All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results - Authors' reply
- PMID: 37652598
- DOI: 10.1016/S2352-3026(23)00242-9
All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results - Authors' reply
Conflict of interest statement
HD declares consultancy fees from AbbVie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Janssen, Jazz Pharmaceuticals, Novartis, Servier, Stemline, and Syndax, and clinical research funding to the institution from AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, Novartis, and Pfizer. AB and AG declare no competing interests.
Comment on
-
All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results.Lancet Haematol. 2023 Sep;10(9):e706-e707. doi: 10.1016/S2352-3026(23)00237-5. Lancet Haematol. 2023. PMID: 37652597 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
